In summary, MRPS7 and MRPS23 are pivotal oncogenic drivers in NPC, and their inhibition, particularly in combination with USP10 targeting, offers a promising strategy to enhance cisplatin efficacy and improve patient outcomes. This evidence concerns the gene MRPS7 and nasopharyngeal carcinoma.